Compare Biogen Inc (BIIB) vs PAGSEG Inc (PAGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs PAGSEG Inc — how do they compare? Biogen Inc trades at $191 (market cap $28.34B), while PAGSEG Inc trades at $9.24 (market cap $2.59B). The key difference: Biogen Inc is far larger — about 10.9× PAGSEG Inc's market cap, and PAGSEG Inc pays a 11.21% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | PAGS | |
|---|---|---|
Market Cap | $28.34B | $2.59B |
Sector | Health | Technology |
52-Week High | $216.63 | $12.00 |
52-Week Low | $122.68 | $7.75 |
Enterprise Value | $30.62B | $10.22B |
Dividend Yield | — | 11.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
PAGS trades at $9.28, up 0.32% on the day, with a bullish technical signal from moving averages. The stock shows strong value metrics with a P/E of 6.57 and P/S of 0.68, supported by solid profitability including a 10.4% net income margin. Recent Q1 2026 earnings missed expectations at $0.39 per share versus $0.40 expected, but Q4 2025 beat estimates. The company maintains robust cash flow from operations of $7.56 billion in 2025.
Outlook remains positive due to deep valuation discounts and analyst consensus favoring buys (62.5%). Key risks include Brazilian macroeconomic sensitivity and competitive pressures in digital banking. Upside potential hinges on execution in credit expansion and efficiency gains, with the stock positioned for recovery if rate cuts materialize in Brazil.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About PAGSEG Inc
PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.
Read more on PAGS →
